Beximco Pharmaceuticals PLC (AIM: BXP), the Bangladesh-based generic pharmaceuticals manufacturer and active pharmaceutical ingredients producer, has appointed Chief Operating Officer S. M. Rabbur Reza as Managing Director with immediate effect, the company announced on 13 November 2026. The five-year appointment follows the departure of former Managing Director Iqbal Ahmed, who was confirmed as stepping down in a separate announcement dated 30 September 2026 and will continue as a non-executive Director. The appointment remains subject to shareholder approval at the company's next Annual General Meeting, making the outcome a near-term event for investors to monitor.

Key Points

  • Beximco Pharmaceuticals PLC (AIM: BXP), LEI No.: 213800IMBBD6TIOQGB56
  • S. M. Rabbur Reza appointed Managing Director for a five-year term with immediate effect, succeeding Iqbal Ahmed
  • Reza, aged 58, has served as COO since 2009 and holds 550 ordinary shares, representing 0.00% of the company's capital
  • Shareholders must ratify the appointment at the next Annual General Meeting

Rabbur Reza's Three Decades of Pharmaceutical Leadership at Beximco Pharma

Reza brings over 30 years of pharmaceutical industry experience to the Managing Director role, having served as Chief Operating Officer at Beximco Pharma since 2009. During his tenure he played a central role in expanding the company's export reach to over 60 countries, including the USA, Australia, and markets across Europe. He also oversaw the strategic acquisitions of Nuvista Pharma and Sanofi Bangladesh, now operating as Synovia Pharma. Reza holds a Bachelor of Pharmacy degree from Panjab University, India, and an MBA from Queensland University of Technology, Australia, and has completed executive education at Harvard Business School, London Business School, and MIT Sloan School of Management.

First-to-Market Generics Strategy, Including 2026 Launch of Cystic Fibrosis Therapy Triko

A defining feature of Reza's operational record at Beximco Pharma has been pioneering first-to-market generic medicines, including breakthrough treatments for hepatitis C and COVID-19. Most recently, in 2026 he led the launch of Triko, the company's generic version of Vertex Pharmaceuticals' cystic fibrosis therapy Trikafta, described in the announcement as the first generic version of that treatment. Beximco Pharma's manufacturing facilities hold regulatory certifications from authorities in the USA, Europe, Australia, Canada, the GCC, and Latin America, supporting the company's ability to commercialise specialist generic products across regulated international markets.

Iqbal Ahmed's Transition to Non-Executive Role and AGM Ratification Requirement

The leadership change was first signalled in Beximco Pharma's announcement of 30 September 2026, which confirmed Iqbal Ahmed's departure from the Managing Director position. Ahmed will remain on the board in a non-executive capacity, providing continuity at board level during the transition. Reza's appointment carries immediate operational authority, though formal shareholder ratification is still required at the next Annual General Meeting. Investors will be watching whether the AGM vote proceeds without complication, as the approval process represents the remaining procedural step before the appointment is fully confirmed under AIM rules.

Beximco Pharma's Global Manufacturing Footprint and 6,000-Strong Workforce

Founded in 1976 and headquartered in Bangladesh, Beximco Pharmaceuticals operates across more than 50 countries and employs over 6,000 people. The company manufactures a broad portfolio of generic dosage forms — ranging from tablets and inhalers to insulins, prefilled syringes, and oral soluble films — and also provides contract manufacturing services for multinational and global generic pharmaceutical companies. As an AIM-listed business with internationally certified manufacturing facilities, the company's growth strategy continues to centre on export expansion and the introduction of specialty and innovative generic therapies into regulated markets worldwide.